nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2C19—Rosuvastatin—atherosclerosis	0.0697	0.123	CbGbCtD
Atomoxetine—CYP2C19—Simvastatin—atherosclerosis	0.0648	0.114	CbGbCtD
Atomoxetine—CYP2C19—Lovastatin—atherosclerosis	0.0635	0.112	CbGbCtD
Atomoxetine—CYP2D6—Niacin—atherosclerosis	0.0624	0.11	CbGbCtD
Atomoxetine—CYP2D6—Simvastatin—atherosclerosis	0.0493	0.087	CbGbCtD
Atomoxetine—CYP2D6—Pravastatin—atherosclerosis	0.0482	0.0852	CbGbCtD
Atomoxetine—CYP2D6—Lovastatin—atherosclerosis	0.0482	0.0852	CbGbCtD
Atomoxetine—CYP3A4—Rosuvastatin—atherosclerosis	0.0337	0.0595	CbGbCtD
Atomoxetine—CYP3A4—Ezetimibe—atherosclerosis	0.0337	0.0595	CbGbCtD
Atomoxetine—CYP3A4—Simvastatin—atherosclerosis	0.0313	0.0553	CbGbCtD
Atomoxetine—CYP3A4—Lovastatin—atherosclerosis	0.0307	0.0542	CbGbCtD
Atomoxetine—CYP3A4—Pravastatin—atherosclerosis	0.0307	0.0542	CbGbCtD
Atomoxetine—HTR2A—arteriole—atherosclerosis	0.00628	0.158	CbGeAlD
Atomoxetine—HTR2A—vein—atherosclerosis	0.00375	0.0945	CbGeAlD
Atomoxetine—HTR1B—artery—atherosclerosis	0.00317	0.08	CbGeAlD
Atomoxetine—HTR1D—artery—atherosclerosis	0.00307	0.0775	CbGeAlD
Atomoxetine—HTR2A—hindlimb—atherosclerosis	0.00249	0.0628	CbGeAlD
Atomoxetine—HTR1B—blood vessel—atherosclerosis	0.00247	0.0623	CbGeAlD
Atomoxetine—HTR1D—blood vessel—atherosclerosis	0.00239	0.0604	CbGeAlD
Atomoxetine—NPY1R—adipose tissue—atherosclerosis	0.00229	0.0578	CbGeAlD
Atomoxetine—HTR2A—appendage—atherosclerosis	0.00213	0.0539	CbGeAlD
Atomoxetine—NPY1R—liver—atherosclerosis	0.00161	0.0405	CbGeAlD
Atomoxetine—HTR2A—artery—atherosclerosis	0.00153	0.0385	CbGeAlD
Atomoxetine—HTR2A—endothelium—atherosclerosis	0.00129	0.0325	CbGeAlD
Atomoxetine—HTR1D—connective tissue—atherosclerosis	0.00123	0.0309	CbGeAlD
Atomoxetine—HTR2A—blood vessel—atherosclerosis	0.00119	0.03	CbGeAlD
Atomoxetine—Pheniramine—HRH1—atherosclerosis	0.00116	0.112	CrCbGaD
Atomoxetine—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00113	0.00493	CcSEcCtD
Atomoxetine—Abdominal discomfort—Simvastatin—atherosclerosis	0.00112	0.00489	CcSEcCtD
Atomoxetine—HTR1B—cardiovascular system—atherosclerosis	0.0011	0.0278	CbGeAlD
Atomoxetine—Nasopharyngitis—Pravastatin—atherosclerosis	0.0011	0.00477	CcSEcCtD
Atomoxetine—Infestation—Ezetimibe—atherosclerosis	0.0011	0.00477	CcSEcCtD
Atomoxetine—Infestation NOS—Ezetimibe—atherosclerosis	0.0011	0.00477	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.00109	0.00474	CcSEcCtD
Atomoxetine—Erectile dysfunction—Simvastatin—atherosclerosis	0.00108	0.0047	CcSEcCtD
Atomoxetine—Influenza—Niacin—atherosclerosis	0.00108	0.00469	CcSEcCtD
Atomoxetine—HTR1D—cardiovascular system—atherosclerosis	0.00107	0.0269	CbGeAlD
Atomoxetine—Influenza—Pravastatin—atherosclerosis	0.00106	0.00462	CcSEcCtD
Atomoxetine—Clofedanol—HRH1—atherosclerosis	0.00105	0.102	CrCbGaD
Atomoxetine—Sinusitis—Lovastatin—atherosclerosis	0.00105	0.00457	CcSEcCtD
Atomoxetine—Depression—Simvastatin—atherosclerosis	0.00104	0.00454	CcSEcCtD
Atomoxetine—Mental disorder—Rosuvastatin—atherosclerosis	0.00104	0.00452	CcSEcCtD
Atomoxetine—Sweating increased—Pravastatin—atherosclerosis	0.00103	0.0045	CcSEcCtD
Atomoxetine—Sinusitis—Ezetimibe—atherosclerosis	0.00103	0.00448	CcSEcCtD
Atomoxetine—Flatulence—Rosuvastatin—atherosclerosis	0.00101	0.00442	CcSEcCtD
Atomoxetine—Erectile dysfunction—Niacin—atherosclerosis	0.000991	0.00432	CcSEcCtD
Atomoxetine—Dysuria—Pravastatin—atherosclerosis	0.000991	0.00432	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000985	0.00429	CcSEcCtD
Atomoxetine—Sinusitis—Simvastatin—atherosclerosis	0.00098	0.00427	CcSEcCtD
Atomoxetine—Erectile dysfunction—Pravastatin—atherosclerosis	0.000976	0.00425	CcSEcCtD
Atomoxetine—Doxylamine—HRH1—atherosclerosis	0.000963	0.0933	CrCbGaD
Atomoxetine—Weight decreased—Pravastatin—atherosclerosis	0.000958	0.00418	CcSEcCtD
Atomoxetine—Depression—Pravastatin—atherosclerosis	0.000942	0.0041	CcSEcCtD
Atomoxetine—Flushing—Lovastatin—atherosclerosis	0.000931	0.00405	CcSEcCtD
Atomoxetine—Diphenylpyraline—HRH1—atherosclerosis	0.000916	0.0888	CrCbGaD
Atomoxetine—Flushing—Ezetimibe—atherosclerosis	0.000913	0.00398	CcSEcCtD
Atomoxetine—Chills—Lovastatin—atherosclerosis	0.0009	0.00392	CcSEcCtD
Atomoxetine—Cough—Rosuvastatin—atherosclerosis	0.000899	0.00392	CcSEcCtD
Atomoxetine—Angiopathy—Ezetimibe—atherosclerosis	0.000892	0.00389	CcSEcCtD
Atomoxetine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000886	0.00386	CcSEcCtD
Atomoxetine—Sinusitis—Pravastatin—atherosclerosis	0.000886	0.00386	CcSEcCtD
Atomoxetine—Arthralgia—Rosuvastatin—atherosclerosis	0.000877	0.00382	CcSEcCtD
Atomoxetine—Myalgia—Rosuvastatin—atherosclerosis	0.000877	0.00382	CcSEcCtD
Atomoxetine—Flushing—Simvastatin—atherosclerosis	0.00087	0.00379	CcSEcCtD
Atomoxetine—Mental disorder—Ezetimibe—atherosclerosis	0.000862	0.00375	CcSEcCtD
Atomoxetine—Flatulence—Lovastatin—atherosclerosis	0.00086	0.00375	CcSEcCtD
Atomoxetine—Hypoaesthesia—Niacin—atherosclerosis	0.000857	0.00373	CcSEcCtD
Atomoxetine—Malnutrition—Ezetimibe—atherosclerosis	0.000856	0.00373	CcSEcCtD
Atomoxetine—Dysgeusia—Lovastatin—atherosclerosis	0.000855	0.00372	CcSEcCtD
Atomoxetine—Back pain—Lovastatin—atherosclerosis	0.000844	0.00368	CcSEcCtD
Atomoxetine—Hypoaesthesia—Pravastatin—atherosclerosis	0.000844	0.00368	CcSEcCtD
Atomoxetine—Flatulence—Ezetimibe—atherosclerosis	0.000844	0.00368	CcSEcCtD
Atomoxetine—Chills—Simvastatin—atherosclerosis	0.000842	0.00367	CcSEcCtD
Atomoxetine—Muscle spasms—Lovastatin—atherosclerosis	0.000839	0.00366	CcSEcCtD
Atomoxetine—Infection—Rosuvastatin—atherosclerosis	0.000835	0.00364	CcSEcCtD
Atomoxetine—Back pain—Ezetimibe—atherosclerosis	0.000828	0.00361	CcSEcCtD
Atomoxetine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000824	0.00359	CcSEcCtD
Atomoxetine—Muscle spasms—Ezetimibe—atherosclerosis	0.000823	0.00359	CcSEcCtD
Atomoxetine—Vision blurred—Lovastatin—atherosclerosis	0.000823	0.00358	CcSEcCtD
Atomoxetine—Mental disorder—Simvastatin—atherosclerosis	0.000822	0.00358	CcSEcCtD
Atomoxetine—Tremor—Lovastatin—atherosclerosis	0.000818	0.00356	CcSEcCtD
Atomoxetine—Flatulence—Simvastatin—atherosclerosis	0.000805	0.0035	CcSEcCtD
Atomoxetine—Dysgeusia—Simvastatin—atherosclerosis	0.0008	0.00348	CcSEcCtD
Atomoxetine—Flushing—Niacin—atherosclerosis	0.000799	0.00348	CcSEcCtD
Atomoxetine—Flushing—Pravastatin—atherosclerosis	0.000787	0.00343	CcSEcCtD
Atomoxetine—Cardiac disorder—Pravastatin—atherosclerosis	0.000787	0.00343	CcSEcCtD
Atomoxetine—Muscle spasms—Simvastatin—atherosclerosis	0.000785	0.00342	CcSEcCtD
Atomoxetine—Vertigo—Lovastatin—atherosclerosis	0.000784	0.00342	CcSEcCtD
Atomoxetine—Angiopathy—Niacin—atherosclerosis	0.000781	0.0034	CcSEcCtD
Atomoxetine—Chills—Niacin—atherosclerosis	0.000773	0.00337	CcSEcCtD
Atomoxetine—Vision blurred—Simvastatin—atherosclerosis	0.000769	0.00335	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000766	0.00334	CcSEcCtD
Atomoxetine—Tremor—Simvastatin—atherosclerosis	0.000765	0.00333	CcSEcCtD
Atomoxetine—Chills—Pravastatin—atherosclerosis	0.000761	0.00331	CcSEcCtD
Atomoxetine—Insomnia—Rosuvastatin—atherosclerosis	0.00076	0.00331	CcSEcCtD
Atomoxetine—Palpitations—Ezetimibe—atherosclerosis	0.000757	0.0033	CcSEcCtD
Atomoxetine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000755	0.00329	CcSEcCtD
Atomoxetine—Bromodiphenhydramine—HRH1—atherosclerosis	0.000753	0.073	CrCbGaD
Atomoxetine—Malnutrition—Niacin—atherosclerosis	0.00075	0.00327	CcSEcCtD
Atomoxetine—Cough—Ezetimibe—atherosclerosis	0.000747	0.00325	CcSEcCtD
Atomoxetine—Myalgia—Lovastatin—atherosclerosis	0.000743	0.00324	CcSEcCtD
Atomoxetine—Chest pain—Lovastatin—atherosclerosis	0.000743	0.00324	CcSEcCtD
Atomoxetine—Arthralgia—Lovastatin—atherosclerosis	0.000743	0.00324	CcSEcCtD
Atomoxetine—Anxiety—Lovastatin—atherosclerosis	0.000741	0.00323	CcSEcCtD
Atomoxetine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00074	0.00322	CcSEcCtD
Atomoxetine—Flatulence—Niacin—atherosclerosis	0.000739	0.00322	CcSEcCtD
Atomoxetine—Cyclizine—HRH1—atherosclerosis	0.000737	0.0714	CrCbGaD
Atomoxetine—Tension—Niacin—atherosclerosis	0.000736	0.0032	CcSEcCtD
Atomoxetine—Vertigo—Simvastatin—atherosclerosis	0.000734	0.0032	CcSEcCtD
Atomoxetine—Myalgia—Ezetimibe—atherosclerosis	0.000729	0.00318	CcSEcCtD
Atomoxetine—Arthralgia—Ezetimibe—atherosclerosis	0.000729	0.00318	CcSEcCtD
Atomoxetine—Chest pain—Ezetimibe—atherosclerosis	0.000729	0.00318	CcSEcCtD
Atomoxetine—Nervousness—Niacin—atherosclerosis	0.000728	0.00317	CcSEcCtD
Atomoxetine—Flatulence—Pravastatin—atherosclerosis	0.000727	0.00317	CcSEcCtD
Atomoxetine—Dry mouth—Lovastatin—atherosclerosis	0.000727	0.00317	CcSEcCtD
Atomoxetine—Tension—Pravastatin—atherosclerosis	0.000724	0.00316	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000724	0.00315	CcSEcCtD
Atomoxetine—Dysgeusia—Pravastatin—atherosclerosis	0.000723	0.00315	CcSEcCtD
Atomoxetine—Muscle spasms—Niacin—atherosclerosis	0.000721	0.00314	CcSEcCtD
Atomoxetine—Constipation—Rosuvastatin—atherosclerosis	0.000719	0.00313	CcSEcCtD
Atomoxetine—Pain—Rosuvastatin—atherosclerosis	0.000719	0.00313	CcSEcCtD
Atomoxetine—Nervousness—Pravastatin—atherosclerosis	0.000717	0.00312	CcSEcCtD
Atomoxetine—Dry mouth—Ezetimibe—atherosclerosis	0.000713	0.00311	CcSEcCtD
Atomoxetine—Muscle spasms—Pravastatin—atherosclerosis	0.00071	0.00309	CcSEcCtD
Atomoxetine—Infection—Lovastatin—atherosclerosis	0.000708	0.00308	CcSEcCtD
Atomoxetine—Vision blurred—Niacin—atherosclerosis	0.000707	0.00308	CcSEcCtD
Atomoxetine—Benzatropine—HRH1—atherosclerosis	0.000703	0.0681	CrCbGaD
Atomoxetine—Vision blurred—Pravastatin—atherosclerosis	0.000696	0.00303	CcSEcCtD
Atomoxetine—Chest pain—Simvastatin—atherosclerosis	0.000695	0.00303	CcSEcCtD
Atomoxetine—Arthralgia—Simvastatin—atherosclerosis	0.000695	0.00303	CcSEcCtD
Atomoxetine—Myalgia—Simvastatin—atherosclerosis	0.000695	0.00303	CcSEcCtD
Atomoxetine—Infection—Ezetimibe—atherosclerosis	0.000694	0.00302	CcSEcCtD
Atomoxetine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000693	0.00302	CcSEcCtD
Atomoxetine—Anxiety—Simvastatin—atherosclerosis	0.000693	0.00302	CcSEcCtD
Atomoxetine—Tremor—Pravastatin—atherosclerosis	0.000692	0.00301	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000687	0.00299	CcSEcCtD
Atomoxetine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000685	0.00299	CcSEcCtD
Atomoxetine—Anorexia—Lovastatin—atherosclerosis	0.000679	0.00296	CcSEcCtD
Atomoxetine—Skin disorder—Ezetimibe—atherosclerosis	0.000679	0.00296	CcSEcCtD
Atomoxetine—Vertigo—Niacin—atherosclerosis	0.000674	0.00293	CcSEcCtD
Atomoxetine—Syncope—Niacin—atherosclerosis	0.000672	0.00293	CcSEcCtD
Atomoxetine—Urticaria—Rosuvastatin—atherosclerosis	0.000668	0.00291	CcSEcCtD
Atomoxetine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000665	0.00289	CcSEcCtD
Atomoxetine—Vertigo—Pravastatin—atherosclerosis	0.000663	0.00289	CcSEcCtD
Atomoxetine—Palpitations—Niacin—atherosclerosis	0.000662	0.00289	CcSEcCtD
Atomoxetine—Infection—Simvastatin—atherosclerosis	0.000662	0.00288	CcSEcCtD
Atomoxetine—Loss of consciousness—Niacin—atherosclerosis	0.000659	0.00287	CcSEcCtD
Atomoxetine—Cough—Niacin—atherosclerosis	0.000654	0.00285	CcSEcCtD
Atomoxetine—Maprotiline—HRH1—atherosclerosis	0.000651	0.063	CrCbGaD
Atomoxetine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000649	0.00283	CcSEcCtD
Atomoxetine—Insomnia—Lovastatin—atherosclerosis	0.000644	0.00281	CcSEcCtD
Atomoxetine—Cough—Pravastatin—atherosclerosis	0.000644	0.00281	CcSEcCtD
Atomoxetine—Paraesthesia—Lovastatin—atherosclerosis	0.00064	0.00279	CcSEcCtD
Atomoxetine—Myalgia—Niacin—atherosclerosis	0.000638	0.00278	CcSEcCtD
Atomoxetine—Arthralgia—Niacin—atherosclerosis	0.000638	0.00278	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000637	0.00277	CcSEcCtD
Atomoxetine—Anorexia—Simvastatin—atherosclerosis	0.000635	0.00277	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000634	0.00276	CcSEcCtD
Atomoxetine—Insomnia—Ezetimibe—atherosclerosis	0.000632	0.00275	CcSEcCtD
Atomoxetine—Arthralgia—Pravastatin—atherosclerosis	0.000628	0.00274	CcSEcCtD
Atomoxetine—Chest pain—Pravastatin—atherosclerosis	0.000628	0.00274	CcSEcCtD
Atomoxetine—Myalgia—Pravastatin—atherosclerosis	0.000628	0.00274	CcSEcCtD
Atomoxetine—Paraesthesia—Ezetimibe—atherosclerosis	0.000627	0.00273	CcSEcCtD
Atomoxetine—Dyspepsia—Lovastatin—atherosclerosis	0.000627	0.00273	CcSEcCtD
Atomoxetine—Anxiety—Pravastatin—atherosclerosis	0.000626	0.00273	CcSEcCtD
Atomoxetine—Dry mouth—Niacin—atherosclerosis	0.000624	0.00272	CcSEcCtD
Atomoxetine—Decreased appetite—Lovastatin—atherosclerosis	0.000619	0.0027	CcSEcCtD
Atomoxetine—Dyspepsia—Ezetimibe—atherosclerosis	0.000615	0.00268	CcSEcCtD
Atomoxetine—Fatigue—Lovastatin—atherosclerosis	0.000614	0.00268	CcSEcCtD
Atomoxetine—HTR2A—connective tissue—atherosclerosis	0.000609	0.0154	CbGeAlD
Atomoxetine—Pain—Lovastatin—atherosclerosis	0.000609	0.00265	CcSEcCtD
Atomoxetine—Constipation—Lovastatin—atherosclerosis	0.000609	0.00265	CcSEcCtD
Atomoxetine—Decreased appetite—Ezetimibe—atherosclerosis	0.000607	0.00265	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000607	0.00264	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000603	0.00263	CcSEcCtD
Atomoxetine—Asthenia—Rosuvastatin—atherosclerosis	0.000603	0.00263	CcSEcCtD
Atomoxetine—Insomnia—Simvastatin—atherosclerosis	0.000603	0.00263	CcSEcCtD
Atomoxetine—Fatigue—Ezetimibe—atherosclerosis	0.000602	0.00262	CcSEcCtD
Atomoxetine—Shock—Niacin—atherosclerosis	0.000602	0.00262	CcSEcCtD
Atomoxetine—Infection—Pravastatin—atherosclerosis	0.000598	0.00261	CcSEcCtD
Atomoxetine—Paraesthesia—Simvastatin—atherosclerosis	0.000598	0.00261	CcSEcCtD
Atomoxetine—Constipation—Ezetimibe—atherosclerosis	0.000598	0.0026	CcSEcCtD
Atomoxetine—Pain—Ezetimibe—atherosclerosis	0.000598	0.0026	CcSEcCtD
Atomoxetine—Tachycardia—Niacin—atherosclerosis	0.000597	0.0026	CcSEcCtD
Atomoxetine—Pruritus—Rosuvastatin—atherosclerosis	0.000595	0.00259	CcSEcCtD
Atomoxetine—Skin disorder—Niacin—atherosclerosis	0.000594	0.00259	CcSEcCtD
Atomoxetine—Hyperhidrosis—Niacin—atherosclerosis	0.000591	0.00258	CcSEcCtD
Atomoxetine—Feeling abnormal—Lovastatin—atherosclerosis	0.000587	0.00256	CcSEcCtD
Atomoxetine—Dyspepsia—Simvastatin—atherosclerosis	0.000587	0.00256	CcSEcCtD
Atomoxetine—Anorexia—Niacin—atherosclerosis	0.000583	0.00254	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000583	0.00254	CcSEcCtD
Atomoxetine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000582	0.00254	CcSEcCtD
Atomoxetine—Decreased appetite—Simvastatin—atherosclerosis	0.000579	0.00252	CcSEcCtD
Atomoxetine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000576	0.00251	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000575	0.00251	CcSEcCtD
Atomoxetine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000575	0.00251	CcSEcCtD
Atomoxetine—Fatigue—Simvastatin—atherosclerosis	0.000574	0.0025	CcSEcCtD
Atomoxetine—Anorexia—Pravastatin—atherosclerosis	0.000574	0.0025	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000571	0.00249	CcSEcCtD
Atomoxetine—Constipation—Simvastatin—atherosclerosis	0.00057	0.00248	CcSEcCtD
Atomoxetine—Pain—Simvastatin—atherosclerosis	0.00057	0.00248	CcSEcCtD
Atomoxetine—Urticaria—Lovastatin—atherosclerosis	0.000566	0.00247	CcSEcCtD
Atomoxetine—Body temperature increased—Lovastatin—atherosclerosis	0.000563	0.00245	CcSEcCtD
Atomoxetine—Abdominal pain—Lovastatin—atherosclerosis	0.000563	0.00245	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000557	0.00243	CcSEcCtD
Atomoxetine—Dizziness—Rosuvastatin—atherosclerosis	0.000556	0.00242	CcSEcCtD
Atomoxetine—Urticaria—Ezetimibe—atherosclerosis	0.000555	0.00242	CcSEcCtD
Atomoxetine—Insomnia—Niacin—atherosclerosis	0.000553	0.00241	CcSEcCtD
Atomoxetine—Body temperature increased—Ezetimibe—atherosclerosis	0.000552	0.00241	CcSEcCtD
Atomoxetine—Abdominal pain—Ezetimibe—atherosclerosis	0.000552	0.00241	CcSEcCtD
Atomoxetine—Paraesthesia—Niacin—atherosclerosis	0.000549	0.00239	CcSEcCtD
Atomoxetine—Feeling abnormal—Simvastatin—atherosclerosis	0.000549	0.00239	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000549	0.00239	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000545	0.00237	CcSEcCtD
Atomoxetine—Insomnia—Pravastatin—atherosclerosis	0.000545	0.00237	CcSEcCtD
Atomoxetine—Somnolence—Niacin—atherosclerosis	0.000544	0.00237	CcSEcCtD
Atomoxetine—Paraesthesia—Pravastatin—atherosclerosis	0.000541	0.00236	CcSEcCtD
Atomoxetine—Dyspepsia—Niacin—atherosclerosis	0.000539	0.00235	CcSEcCtD
Atomoxetine—Decreased appetite—Niacin—atherosclerosis	0.000532	0.00232	CcSEcCtD
Atomoxetine—Dyspepsia—Pravastatin—atherosclerosis	0.00053	0.00231	CcSEcCtD
Atomoxetine—HTR2A—cardiovascular system—atherosclerosis	0.00053	0.0134	CbGeAlD
Atomoxetine—Rash—Rosuvastatin—atherosclerosis	0.00053	0.00231	CcSEcCtD
Atomoxetine—Dermatitis—Rosuvastatin—atherosclerosis	0.00053	0.00231	CcSEcCtD
Atomoxetine—Urticaria—Simvastatin—atherosclerosis	0.000529	0.00231	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000528	0.0023	CcSEcCtD
Atomoxetine—Body temperature increased—Simvastatin—atherosclerosis	0.000527	0.00229	CcSEcCtD
Atomoxetine—Abdominal pain—Simvastatin—atherosclerosis	0.000527	0.00229	CcSEcCtD
Atomoxetine—Headache—Rosuvastatin—atherosclerosis	0.000527	0.00229	CcSEcCtD
Atomoxetine—Decreased appetite—Pravastatin—atherosclerosis	0.000524	0.00228	CcSEcCtD
Atomoxetine—Pain—Niacin—atherosclerosis	0.000523	0.00228	CcSEcCtD
Atomoxetine—Fatigue—Pravastatin—atherosclerosis	0.000519	0.00226	CcSEcCtD
Atomoxetine—Pain—Pravastatin—atherosclerosis	0.000515	0.00224	CcSEcCtD
Atomoxetine—Constipation—Pravastatin—atherosclerosis	0.000515	0.00224	CcSEcCtD
Atomoxetine—CYP2C19—liver—atherosclerosis	0.000513	0.013	CbGeAlD
Atomoxetine—Asthenia—Lovastatin—atherosclerosis	0.000511	0.00223	CcSEcCtD
Atomoxetine—Pruritus—Lovastatin—atherosclerosis	0.000504	0.0022	CcSEcCtD
Atomoxetine—Asthenia—Ezetimibe—atherosclerosis	0.000501	0.00218	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Niacin—atherosclerosis	0.0005	0.00218	CcSEcCtD
Atomoxetine—Nausea—Rosuvastatin—atherosclerosis	0.000499	0.00218	CcSEcCtD
Atomoxetine—Feeling abnormal—Pravastatin—atherosclerosis	0.000496	0.00216	CcSEcCtD
Atomoxetine—Pruritus—Ezetimibe—atherosclerosis	0.000494	0.00215	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000493	0.00215	CcSEcCtD
Atomoxetine—Diarrhoea—Lovastatin—atherosclerosis	0.000487	0.00212	CcSEcCtD
Atomoxetine—Urticaria—Niacin—atherosclerosis	0.000486	0.00212	CcSEcCtD
Atomoxetine—Abdominal pain—Niacin—atherosclerosis	0.000484	0.00211	CcSEcCtD
Atomoxetine—Body temperature increased—Niacin—atherosclerosis	0.000484	0.00211	CcSEcCtD
Atomoxetine—Urticaria—Pravastatin—atherosclerosis	0.000479	0.00208	CcSEcCtD
Atomoxetine—Asthenia—Simvastatin—atherosclerosis	0.000478	0.00208	CcSEcCtD
Atomoxetine—Diarrhoea—Ezetimibe—atherosclerosis	0.000478	0.00208	CcSEcCtD
Atomoxetine—Body temperature increased—Pravastatin—atherosclerosis	0.000476	0.00207	CcSEcCtD
Atomoxetine—Abdominal pain—Pravastatin—atherosclerosis	0.000476	0.00207	CcSEcCtD
Atomoxetine—Pruritus—Simvastatin—atherosclerosis	0.000471	0.00205	CcSEcCtD
Atomoxetine—Dizziness—Lovastatin—atherosclerosis	0.000471	0.00205	CcSEcCtD
Atomoxetine—Dizziness—Ezetimibe—atherosclerosis	0.000462	0.00201	CcSEcCtD
Atomoxetine—Diarrhoea—Simvastatin—atherosclerosis	0.000456	0.00199	CcSEcCtD
Atomoxetine—Vomiting—Lovastatin—atherosclerosis	0.000453	0.00197	CcSEcCtD
Atomoxetine—Rash—Lovastatin—atherosclerosis	0.000449	0.00196	CcSEcCtD
Atomoxetine—Dermatitis—Lovastatin—atherosclerosis	0.000449	0.00196	CcSEcCtD
Atomoxetine—Headache—Lovastatin—atherosclerosis	0.000446	0.00194	CcSEcCtD
Atomoxetine—Vomiting—Ezetimibe—atherosclerosis	0.000444	0.00194	CcSEcCtD
Atomoxetine—Dizziness—Simvastatin—atherosclerosis	0.000441	0.00192	CcSEcCtD
Atomoxetine—Rash—Ezetimibe—atherosclerosis	0.000441	0.00192	CcSEcCtD
Atomoxetine—Dermatitis—Ezetimibe—atherosclerosis	0.00044	0.00192	CcSEcCtD
Atomoxetine—Asthenia—Niacin—atherosclerosis	0.000439	0.00191	CcSEcCtD
Atomoxetine—Headache—Ezetimibe—atherosclerosis	0.000438	0.00191	CcSEcCtD
Atomoxetine—Ketoprofen—CXCL8—atherosclerosis	0.000435	0.0422	CrCbGaD
Atomoxetine—Pruritus—Niacin—atherosclerosis	0.000433	0.00189	CcSEcCtD
Atomoxetine—Asthenia—Pravastatin—atherosclerosis	0.000432	0.00188	CcSEcCtD
Atomoxetine—Pruritus—Pravastatin—atherosclerosis	0.000426	0.00186	CcSEcCtD
Atomoxetine—Vomiting—Simvastatin—atherosclerosis	0.000424	0.00185	CcSEcCtD
Atomoxetine—Nausea—Lovastatin—atherosclerosis	0.000423	0.00184	CcSEcCtD
Atomoxetine—Rash—Simvastatin—atherosclerosis	0.00042	0.00183	CcSEcCtD
Atomoxetine—Dermatitis—Simvastatin—atherosclerosis	0.00042	0.00183	CcSEcCtD
Atomoxetine—Diarrhoea—Niacin—atherosclerosis	0.000419	0.00182	CcSEcCtD
Atomoxetine—Headache—Simvastatin—atherosclerosis	0.000417	0.00182	CcSEcCtD
Atomoxetine—Nausea—Ezetimibe—atherosclerosis	0.000415	0.00181	CcSEcCtD
Atomoxetine—Diarrhoea—Pravastatin—atherosclerosis	0.000412	0.0018	CcSEcCtD
Atomoxetine—Dizziness—Niacin—atherosclerosis	0.000405	0.00176	CcSEcCtD
Atomoxetine—Dizziness—Pravastatin—atherosclerosis	0.000398	0.00174	CcSEcCtD
Atomoxetine—Nausea—Simvastatin—atherosclerosis	0.000396	0.00172	CcSEcCtD
Atomoxetine—Nortriptyline—HRH1—atherosclerosis	0.000391	0.0379	CrCbGaD
Atomoxetine—Vomiting—Niacin—atherosclerosis	0.000389	0.00169	CcSEcCtD
Atomoxetine—Rash—Niacin—atherosclerosis	0.000386	0.00168	CcSEcCtD
Atomoxetine—Dermatitis—Niacin—atherosclerosis	0.000385	0.00168	CcSEcCtD
Atomoxetine—Headache—Niacin—atherosclerosis	0.000383	0.00167	CcSEcCtD
Atomoxetine—Vomiting—Pravastatin—atherosclerosis	0.000383	0.00167	CcSEcCtD
Atomoxetine—Rash—Pravastatin—atherosclerosis	0.00038	0.00165	CcSEcCtD
Atomoxetine—Dermatitis—Pravastatin—atherosclerosis	0.000379	0.00165	CcSEcCtD
Atomoxetine—Headache—Pravastatin—atherosclerosis	0.000377	0.00164	CcSEcCtD
Atomoxetine—Nausea—Niacin—atherosclerosis	0.000363	0.00158	CcSEcCtD
Atomoxetine—Diphenhydramine—HRH1—atherosclerosis	0.000361	0.035	CrCbGaD
Atomoxetine—Nausea—Pravastatin—atherosclerosis	0.000358	0.00156	CcSEcCtD
Atomoxetine—Orphenadrine—HRH1—atherosclerosis	0.000342	0.0331	CrCbGaD
Atomoxetine—Pseudoephedrine—TNF—atherosclerosis	0.00033	0.032	CrCbGaD
Atomoxetine—HTR2A—liver—atherosclerosis	0.000328	0.00827	CbGeAlD
Atomoxetine—Desipramine—HRH1—atherosclerosis	0.000322	0.0312	CrCbGaD
Atomoxetine—CYP3A4—liver—atherosclerosis	0.000304	0.00766	CbGeAlD
Atomoxetine—CYP2D6—liver—atherosclerosis	0.000299	0.00754	CbGeAlD
Atomoxetine—Fenoprofen—PTGS2—atherosclerosis	0.000215	0.0208	CrCbGaD
Atomoxetine—Fenoprofen—ALB—atherosclerosis	0.000192	0.0186	CrCbGaD
Atomoxetine—Phenprocoumon—ALB—atherosclerosis	0.000165	0.016	CrCbGaD
Atomoxetine—Fluoxetine—ALB—atherosclerosis	0.000161	0.0156	CrCbGaD
Atomoxetine—Warfarin—ALB—atherosclerosis	0.000147	0.0142	CrCbGaD
Atomoxetine—Ketoprofen—PTGS2—atherosclerosis	0.000127	0.0123	CrCbGaD
Atomoxetine—Ketoprofen—ALB—atherosclerosis	0.000113	0.011	CrCbGaD
Atomoxetine—Nortriptyline—ALB—atherosclerosis	9.03e-05	0.00874	CrCbGaD
Atomoxetine—CYP2C19—Metabolism—NAMPT—atherosclerosis	1.83e-05	0.000119	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.82e-05	0.000118	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LIPC—atherosclerosis	1.82e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CAV1—atherosclerosis	1.82e-05	0.000118	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCG1—atherosclerosis	1.82e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOA1—atherosclerosis	1.81e-05	0.000118	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOC3—atherosclerosis	1.81e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ESR1—atherosclerosis	1.8e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP3—atherosclerosis	1.8e-05	0.000117	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LDLR—atherosclerosis	1.8e-05	0.000117	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF2—atherosclerosis	1.79e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ESR1—atherosclerosis	1.79e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—F2—atherosclerosis	1.78e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—F2—atherosclerosis	1.77e-05	0.000115	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AKT1—atherosclerosis	1.76e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KNG1—atherosclerosis	1.76e-05	0.000114	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CETP—atherosclerosis	1.76e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ESR1—atherosclerosis	1.75e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGTR1—atherosclerosis	1.75e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOB—atherosclerosis	1.74e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—F2—atherosclerosis	1.73e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCL8—atherosclerosis	1.72e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL2—atherosclerosis	1.72e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EDN1—atherosclerosis	1.71e-05	0.000111	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—FABP4—atherosclerosis	1.71e-05	0.000111	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LCAT—atherosclerosis	1.71e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PLG—atherosclerosis	1.71e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CG—atherosclerosis	1.71e-05	0.000111	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL5—atherosclerosis	1.7e-05	0.00011	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CG—atherosclerosis	1.69e-05	0.00011	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NAMPT—atherosclerosis	1.69e-05	0.000109	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SCARB1—atherosclerosis	1.68e-05	0.000109	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOA4—atherosclerosis	1.68e-05	0.000109	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LIPC—atherosclerosis	1.67e-05	0.000109	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOC3—atherosclerosis	1.66e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LPL—atherosclerosis	1.66e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CG—atherosclerosis	1.66e-05	0.000107	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LDLR—atherosclerosis	1.65e-05	0.000107	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP7A1—atherosclerosis	1.65e-05	0.000107	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	1.64e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK3—atherosclerosis	1.63e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK3—atherosclerosis	1.62e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SOCS3—atherosclerosis	1.62e-05	0.000105	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CETP—atherosclerosis	1.62e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—INS—atherosclerosis	1.61e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRKCG—atherosclerosis	1.61e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—INS—atherosclerosis	1.6e-05	0.000104	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMGCR—atherosclerosis	1.59e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL2—atherosclerosis	1.59e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK3—atherosclerosis	1.59e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL2—atherosclerosis	1.58e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SPP1—atherosclerosis	1.57e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—INS—atherosclerosis	1.57e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL8—atherosclerosis	1.57e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP3—atherosclerosis	1.56e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1—atherosclerosis	1.56e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF2—atherosclerosis	1.56e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1—atherosclerosis	1.55e-05	0.0001	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SCARB1—atherosclerosis	1.55e-05	0.0001	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL2—atherosclerosis	1.54e-05	0.0001	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP27A1—atherosclerosis	1.52e-05	9.88e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1—atherosclerosis	1.52e-05	9.84e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOB—atherosclerosis	1.51e-05	9.79e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL8—atherosclerosis	1.5e-05	9.71e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EDN1—atherosclerosis	1.49e-05	9.64e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SERPINE1—atherosclerosis	1.48e-05	9.62e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL5—atherosclerosis	1.47e-05	9.56e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SERPINE1—atherosclerosis	1.47e-05	9.54e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMGCR—atherosclerosis	1.46e-05	9.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PDGFB—atherosclerosis	1.45e-05	9.44e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOA2—atherosclerosis	1.44e-05	9.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALOX15—atherosclerosis	1.44e-05	9.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	1.44e-05	9.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	1.44e-05	9.37e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LPL—atherosclerosis	1.44e-05	9.35e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SERPINE1—atherosclerosis	1.44e-05	9.34e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.43e-05	9.29e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCG5—atherosclerosis	1.43e-05	9.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGT—atherosclerosis	1.42e-05	9.21e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCA1—atherosclerosis	1.42e-05	9.18e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOS3—atherosclerosis	1.42e-05	9.18e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOS3—atherosclerosis	1.4e-05	9.11e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRKCG—atherosclerosis	1.4e-05	9.09e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LEP—atherosclerosis	1.39e-05	9.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—atherosclerosis	1.39e-05	9.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CAV1—atherosclerosis	1.38e-05	8.94e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LPA—atherosclerosis	1.38e-05	8.94e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOS3—atherosclerosis	1.38e-05	8.92e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOA1—atherosclerosis	1.38e-05	8.92e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SPP1—atherosclerosis	1.37e-05	8.85e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	1.36e-05	8.82e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BGN—atherosclerosis	1.33e-05	8.66e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ESR1—atherosclerosis	1.33e-05	8.62e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOA5—atherosclerosis	1.32e-05	8.57e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—F2—atherosclerosis	1.31e-05	8.51e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCA1—atherosclerosis	1.3e-05	8.45e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	1.27e-05	8.25e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	1.26e-05	8.19e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CG—atherosclerosis	1.26e-05	8.14e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL8—atherosclerosis	1.26e-05	8.14e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL8—atherosclerosis	1.25e-05	8.08e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGT—atherosclerosis	1.23e-05	8e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.23e-05	7.97e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	1.22e-05	7.91e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—HMOX1—atherosclerosis	1.21e-05	7.88e-05	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—atherosclerosis	1.21e-05	7.87e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LEP—atherosclerosis	1.21e-05	7.84e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—atherosclerosis	1.21e-05	7.84e-05	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	1.2e-05	7.81e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	1.2e-05	7.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CAV1—atherosclerosis	1.2e-05	7.76e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOA1—atherosclerosis	1.19e-05	7.75e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—atherosclerosis	1.19e-05	7.74e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INS—atherosclerosis	1.19e-05	7.71e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—atherosclerosis	1.18e-05	7.68e-05	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	1.18e-05	7.64e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL2—atherosclerosis	1.17e-05	7.59e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOB—atherosclerosis	1.16e-05	7.55e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—atherosclerosis	1.16e-05	7.52e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ESR1—atherosclerosis	1.15e-05	7.48e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1—atherosclerosis	1.15e-05	7.46e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—F2—atherosclerosis	1.14e-05	7.39e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—atherosclerosis	1.14e-05	7.37e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—atherosclerosis	1.13e-05	7.34e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—atherosclerosis	1.13e-05	7.31e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NFKB1—atherosclerosis	1.12e-05	7.29e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.12e-05	7.25e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	1.12e-05	7.23e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LPL—atherosclerosis	1.11e-05	7.21e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK8—atherosclerosis	1.1e-05	7.16e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—atherosclerosis	1.1e-05	7.16e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.1e-05	7.15e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—atherosclerosis	1.1e-05	7.14e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	1.1e-05	7.11e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LIPC—atherosclerosis	1.09e-05	7.1e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	1.09e-05	7.09e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	1.09e-05	7.08e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	1.09e-05	7.08e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	1.09e-05	7.07e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOC3—atherosclerosis	1.09e-05	7.06e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPX1—atherosclerosis	1.08e-05	7.03e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LDLR—atherosclerosis	1.08e-05	7.01e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	1.07e-05	6.96e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	1.07e-05	6.94e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOB—atherosclerosis	1.07e-05	6.94e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CETP—atherosclerosis	1.06e-05	6.85e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CD36—atherosclerosis	1.06e-05	6.85e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	1.04e-05	6.77e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOS3—atherosclerosis	1.04e-05	6.76e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.04e-05	6.75e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INS—atherosclerosis	1.03e-05	6.69e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LPL—atherosclerosis	1.02e-05	6.63e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—atherosclerosis	1.02e-05	6.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	1.02e-05	6.59e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	1.01e-05	6.56e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.01e-05	6.56e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—atherosclerosis	1.01e-05	6.55e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—atherosclerosis	1e-05	6.5e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—atherosclerosis	1e-05	6.49e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	9.98e-06	6.48e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPX1—atherosclerosis	9.97e-06	6.47e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	9.91e-06	6.43e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARA—atherosclerosis	9.82e-06	6.37e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—atherosclerosis	9.81e-06	6.36e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CD36—atherosclerosis	9.71e-06	6.3e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK3—atherosclerosis	9.65e-06	6.26e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	9.57e-06	6.21e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMGCR—atherosclerosis	9.55e-06	6.2e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AGT—atherosclerosis	9.51e-06	6.17e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	9.48e-06	6.15e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	9.37e-06	6.08e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—atherosclerosis	9.36e-06	6.07e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—atherosclerosis	9.31e-06	6.04e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	9.29e-06	6.02e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	9.25e-06	6e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CAV1—atherosclerosis	9.23e-06	5.99e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOA1—atherosclerosis	9.21e-06	5.97e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—atherosclerosis	9.2e-06	5.97e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	9.1e-06	5.9e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	9.05e-06	5.87e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARA—atherosclerosis	9.03e-06	5.86e-05	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	8.93e-06	5.79e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	8.79e-06	5.7e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AGT—atherosclerosis	8.74e-06	5.67e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—atherosclerosis	8.57e-06	5.56e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCA1—atherosclerosis	8.52e-06	5.52e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CAV1—atherosclerosis	8.49e-06	5.5e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOA1—atherosclerosis	8.47e-06	5.49e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	8.41e-06	5.45e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	8.36e-06	5.42e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	8.27e-06	5.37e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	8.13e-06	5.28e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PPARG—atherosclerosis	8.11e-06	5.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	8.11e-06	5.26e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	8.03e-06	5.21e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—INS—atherosclerosis	7.96e-06	5.16e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	7.76e-06	5.03e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	7.73e-06	5.01e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	7.64e-06	4.95e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	7.51e-06	4.87e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PPARG—atherosclerosis	7.46e-06	4.84e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	7.44e-06	4.82e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—INS—atherosclerosis	7.32e-06	4.75e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—HMOX1—atherosclerosis	7.31e-06	4.74e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—atherosclerosis	7.29e-06	4.73e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	7.26e-06	4.71e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	7.19e-06	4.66e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	7.1e-06	4.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	7.06e-06	4.58e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—atherosclerosis	7.05e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	7.04e-06	4.57e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—atherosclerosis	7e-06	4.54e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOB—atherosclerosis	7e-06	4.54e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NOS3—atherosclerosis	6.98e-06	4.53e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	6.89e-06	4.47e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—atherosclerosis	6.85e-06	4.45e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—atherosclerosis	6.81e-06	4.42e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—atherosclerosis	6.71e-06	4.35e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LPL—atherosclerosis	6.68e-06	4.33e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	6.52e-06	4.23e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPX1—atherosclerosis	6.52e-06	4.23e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—atherosclerosis	6.51e-06	4.22e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—atherosclerosis	6.46e-06	4.19e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	6.46e-06	4.19e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NOS3—atherosclerosis	6.42e-06	4.16e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—atherosclerosis	6.38e-06	4.14e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CD36—atherosclerosis	6.35e-06	4.12e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—atherosclerosis	6.32e-06	4.1e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	6.17e-06	4e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—atherosclerosis	6.02e-06	3.9e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	5.99e-06	3.88e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARA—atherosclerosis	5.9e-06	3.83e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—atherosclerosis	5.87e-06	3.81e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AGT—atherosclerosis	5.72e-06	3.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—atherosclerosis	5.6e-06	3.63e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CAV1—atherosclerosis	5.55e-06	3.6e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOA1—atherosclerosis	5.54e-06	3.59e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—atherosclerosis	5.19e-06	3.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	5.05e-06	3.28e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PPARG—atherosclerosis	4.88e-06	3.16e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	4.79e-06	3.11e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—INS—atherosclerosis	4.78e-06	3.1e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—atherosclerosis	4.51e-06	2.93e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—atherosclerosis	4.39e-06	2.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NOS3—atherosclerosis	4.2e-06	2.72e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	4.16e-06	2.7e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—atherosclerosis	3.84e-06	2.49e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—atherosclerosis	3.21e-06	2.08e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—atherosclerosis	2.95e-06	1.91e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—atherosclerosis	1.93e-06	1.25e-05	CbGpPWpGaD
